RxDoctor Payments Data

Naomi Amudala, NP

Family · Boston, MANPI 1154655348

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Amgen at 58.4% of the total. 2025 is the largest year on record at $38,342, more than ten times the $48 reported in 2021. Among family clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$78,637in general payments, 2019–2025

Across 151 payments — averaging $520.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$46K
  • Johnson & Johnson$13K
  • Janssen Scientific Affairs, LLC$7K
  • Novartis$5K
  • Eli Lilly$4K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $2K from 4 others

What the payments were for

  • Consulting fees$23,54030%
  • Speaking & faculty fees$38,57949%
  • Travel & lodging$12,40216%
  • Food & beverage$4,0615%
  • Education$550%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,637 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$26,797
Medicare patients
126
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab35$361,688
TavneosAvacopan12$165,315
NucalaMepolizumab13$139,844
Enbrel SureclickEtanercept15$139,172
ActemraTocilizumab40$122,188
Xeljanz XrTofacitinib Citrate11$61,841
Actemra ActpenTocilizumab12$47,670
OtrexupMethotrexate/Pf11$8,132
Hydroxychloroquine Sulfate90$2,411
Mycophenolate Mofetil19$2,185
MethotrexateMethotrexate Sodium78$2,104
Prednisone148$1,373
Azathioprine29$661
Allopurinol16$306
Methotrexate SodiumMethotrexate Sodium/Pf15$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenTavneos$45,945$165,31512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.

Other family in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →